A Weighted U Statistic for Genetic Association Analyses of Sequencing
  Data by Wei, Changshuai et al.
 1 
 
A Weighted U Statistic for Genetic Association Analyses of Sequencing Data 
 
 
Changshuai Wei,1,2 Ming Li,3 Zihuai He,4 Olga Vsevolozhskaya,1 Daniel J. Schaid,5 and Qing Lu1 ∗ 
 
1Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, United States of 
America; 
2Department of Biostatistics and Epidemiology, University of North Texas Health Science Center, Fort Worth, Texas, 
United States of America; 
3Division of Biostatistics, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, 
United States of America; 
4Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, United States of America; 
5Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, United States of America 
 
 
 
Running title: A Weighted U for Sequencing Data Analyses 
 
 
*Correspondence to:  
Qing Lu, Ph.D 
Department of Epidemiology and Biostatistics, Michigan State University;  
B601 West Fee Hall, East Lansing, MI 48824 
Phone: 517.353.8623 x137 
Fax: 517.432.1130 
E-mail: qlu@epi.msu.edu 
 
 
 
 
The article has been published in final format at 
http://onlinelibrary.wiley.com/doi/10.1002/gepi.21864/abstract 
  
 2 
 
Abstract 
With advancements in next generation sequencing technology, a massive amount of sequencing data are 
generated, offering a great opportunity to comprehensively investigate the role of rare variants in the genetic 
etiology of complex diseases. Nevertheless, this poses a great challenge for the statistical analysis of 
high-dimensional sequencing data. The association analyses based on traditional statistical methods suffer 
substantial power loss because of the low frequency of genetic variants and the extremely high dimensionality 
of the data. We developed a weighted U statistic, referred to as WU-SEQ, for the high-dimensional association 
analysis of sequencing data. Based on a non-parametric U statistic, WU-SEQ makes no assumption of the 
underlying disease model and phenotype distribution, and can be applied to a variety of phenotypes. Through 
simulation studies and an empirical study, we showed that WU-SEQ outperformed a commonly used SKAT 
method when the underlying assumptions were violated (e.g., the phenotype followed a heavy-tailed 
distribution). Even when the assumptions were satisfied, WU-SEQ still attained comparable performance to 
SKAT. Finally, we applied WU-SEQ to sequencing data from the Dallas Heart Study (DHS), and detected an 
association between ANGPTL 4 and very low density lipoprotein cholesterol. 
Keywords: rare variants, next generation sequencing, weighted U statistic 
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Introduction 
Genome-wide association studies (GWAS) have been used to uncover common genetic variants predisposing 
to common complex diseases. During the past decade, thousands of new genetic variants have been identified 
from GWAS, some with compelling biological plausibility for a role in disease etiology [Hindorff, et al. 2009]. 
Despite such successes, the genetic variants identified for most complex diseases thus far can only explain a 
small fraction of the total heritability. Evolutionary theory suggests that rare variants are likely to be recent 
mutations, and are also likely to be more deleterious because they are under less negative selective pressure 
[Boyko, et al. 2008; Fay, et al. 2001; Kryukov, et al. 2007; Pritchard 2001; Raychaudhuri 2011]. Converging 
evidence from genetic studies of complex diseases also suggests that complex diseases are highly 
heterogeneous, and that familial subtypes of complex diseases are frequently seen to be caused by rare 
variants with large effects [Ahituv, et al. 2007; Cohen, et al. 2004; Easton, et al. 2007; Ji, et al. 2008; Romeo, 
et al. 2009]. Nevertheless, current findings of rare variants predisposing to complex diseases are still limited. 
With advancements in high-throughput sequencing technology, researchers are now able to comprehensively 
study the role of a massive amount of sequencing variations, including both common and rare variants. While 
the ongoing exome and whole-genome sequencing studies hold great promise for identifying new genetic 
variants, including rare variants, they also pose great challenges for the statistical analysis of massive amounts 
of sequencing data. 
Although single-locus analysis has been widely used in GWAS, such analysis is underpowered for detecting 
rare variants. Rare variants are anticipated to have larger effects than common variants, but their low 
frequencies in the study population make them hard to detect. Moreover, the number of single-locus tests 
required for sequencing studies is significantly larger than those required for GWAS studies, which increases 
the multiple-testing burden. Therefore, as an essential alternative, a joint association analysis of genetic 
variants, became popular in the association analysis of sequencing data [Barnett, et al. 2013; Chen, et al. 2012; 
Ladouceur, et al. 2012; Lee, et al. 2012; Li and Leal 2008; Lin and Tang 2011; Madsen and Browning 2009; 
Morgenthaler and Thilly 2007; Neale, et al. 2011; Wei and Lu 2011; Wu, et al. 2011; Zhu, et al. 2010]. A 
common strategy used in such analysis is to first aggregate the effect of rare variants in a region (e.g., a gene) 
via collapsing or weighting, and then to assess the joint association of the variants with the phenotype of 
interest. By aggregating information from multiple variants, the association signal is enhanced and becomes 
more detectable. Moreover, this greatly reduces the number of tests, which alleviates the multiple-testing issue. 
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The commonly used methods for joint association analysis include the cohort allelic sum test (CAST), the 
combined multivariate and collapsing (CMC) method [Li and Leal 2008] and the weighted sum test (WST) 
[Madsen and Browning 2009]. These methods, however, implicitly assume the effects of different rare 
variants are in the same direction or magnitude. To address this limitation, the C-alpha test [Neale, et al. 2011] 
was proposed to consider the direction and magnitude of effects, whereby the expected variance and observed 
variance were compared in a case-control setting. Another widely used semi-parametric method for 
sequencing data analyses is the sequence kernel association test (SKAT) [Wu, et al. 2011], which is also robust 
for the direction and magnitude of genetic effects. Moreover, built based on the kernel machine regression, 
SKAT can adjust for covariates, and is applicable to both binary and Gaussian phenotypes. 
Most existing methods for sequencing data analyses are parametric-based or semi-parametric based, which 
rely on certain assumptions. However, in practice, these assumptions may not be satisfied (e.g., the phenotype 
may not follow a normal distribution in a sequencing study based on an extreme phenotype design). When the 
assumptions are violated, the existing methods will likely have either decreased power or inflated type I error. 
Non-parametric methods, such as U-statistic-based methods, have shown their robustness against underlying 
phenotypic distributions and/or underlying modes of inheritance [Li 2012; Li, et al. 2011; Schaid, et al. 2005; 
Wei, et al. 2012; Wei, et al. 2013; Wei, et al. 2008]. Various U-statistic-based methods have been proposed to 
identify common variants associated with binary or quantitative phenotypes. Most of these methods use U 
statistic to obtain multiple group-wise scores, and then form test statistics to compare scores among different 
groups. For case-control data analyses, U statistic is used to summarize the genetic information, and then to 
compare scores between cases and controls [Schaid, et al. 2005]. For quantitative data analyses, U statistic 
first summarizes the phenotypic information, and then compares scores among different genotype groups or 
multi-locus genotype groups [Wei, et al. 2008]. Because of different ways of constructing U-statistics for 
binary and quantitative phenotypes, it is challenging to provide a unified method under the traditional 
U-statistic framework [Li 2012].  
The weighted U statistic is a more general form of the U statistic. It was developed in the 1980s-1990s 
[Gregory 1977; Serfling 1981; Shieh 1997] and has rarely been used in genetic data analyses. By using a 
weighted U statistic, genetic information and phenotypic information can be summarized separately into the 
weight function and U kernel, thereby avoid the issue of group score comparison. Based on the weighted U 
statistic, we develop a unified method, referred to as WU-SEQ, for sequencing data analyses of various types 
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of phenotypes (e.g., binary, ordinal, and continuous). Moreover, we use a projection method in WU-SEQ for 
covariates adjustment, and derive the asymptotic distribution of the test statistic for an efficient assessment of 
the significance of the association. The performance of WU-SEQ was evaluated though extensive simulation 
studies, and compared with a commonly used method, SKAT [Wu, et al. 2011]. Finally, we illustrated the 
proposed method by applying WU-SEQ to sequencing data from the Dallas Heart Study (DHS). 
Methods 
A weighted U for association analyses of sequencing data 
Assume a population-based sequencing study with N unrelated subjects and P single nucleotide variants (SNV) 
located in a gene or a genetic region. Let iy  and 1 2( , , , )i i i iPG g g g denote, respectively, the phenotype 
and the genotypes of P variants of an individual i (1 i n  ), where ipg (1 p P  ) is coded as 0, 1, or 2. 
We use , 'i is  and , 'i iw to denote the phenotypic similarity and genetic similarity between individuals i and i’ , 
respectively. The phenotypic similarity can be measured by any 2 degree kernel function, , ' '( , )i i i is h y y , 
which satisfies the finite second moment condition (
2
1 2( ( , ))FE h Y Y  ). While various kernel functions can 
be used to measure the phenotypic similarities, in this paper, we use the cross product kernel, , ' 'i i i is q q , 
where iq  is the normal quantile of the rank of iy , defined as 
1(( ( ) 0.5) / )i iq rank y n
  , and 
1( )   
is the inverse cumulative distribution function for standard normal distribution. In the presence of ties, we 
assign them an averaged rank. For example, if there are 0n  numbers of controls (i.e., 0iy  ) and 1n  
numbers of cases (i.e., 1iy  ), an average rank is assigned to the group with the same phenotype value (e.g.,
0( { , 0}) ( 1) / 2i i irank y y y n     is assigned to the control group). Other than the quantile-transformed 
cross product kernel, distance-transformed phenotypic similarities, such as , ' 'exp( | |)i i i is y y    or 
2
, ' 'exp( ( ) )i i i is y y    can be centralized and be used to measure the phenotypic similarity. Nevertheless, as 
we demonstrate below, the use of the quantile-transformed cross product kernel leads to nice asymptotic 
properties. Genetic similarity, , 'i iw , can be calculated using a variety of similarity functions. One of the 
commonly used similarity functions for sequencing data is the weighted IBS, which gives more weight to rare 
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variants, 
, ',
, '
1
2 | |
(1 )
P
i p i p
i i
p p p
G G
w
 
 

 
 , 
where p  is the minor allele frequency for the p-th rare variant, and 
1
2 / (1 )
P
p p
p
 

    is used to 
standardize the weight function so that , ' [0,1]i iw  . In addition to weighted IBS, distance-transformed 
similarity functions can also be used. For example, we could use , ' , 'exp( )i i i iw D  , where , 'i iD  is the 
distance function (e.g., Euclidian distance). 
Given , 'i is  and , 'i iw , the weighted U is formed to measure the association of P genetic variants with the 
disease phenotype,  
, ' , '
'
1
( 1)
w i i i i
i i
U w s
n n 


 ,         (1) 
where , 'i is  is the 2 degree U kernel and , 'i iw  is the weight function for the weighted U. When , ' 1i iw  , we 
can construct an un-weighted U by using only the phenotype similarity, 
, '
'
1
( 1)
uw i i
i i
U s
n n 


 .         (2) 
In the weighted U, the summation is over all phenotypic similarities weighted by the genotypic similarity, 
whereas only the phenotypic similarity is used for the un-weighted U. Note that the U kernel, , 'i is , could be a 
positive/negative value with a mean of 0. When there is no association (i.e., under the null), both the 
un-weighted U and the weighted U have an expectation of 0. When the genetic variants are associated with the 
phenotype, we would expect genetic similarities to be concordant with phenotypic similarities, where larger 
weights are given to larger values of phenotypic similarity. Therefore, the weighted U is expected to have a 
positive value, while the un-weighted U remains have an expectation of 0 (i.e., the weighted U is expected to 
be greater than the un-weighted U). Based on this concept, we could build an association test by comparing 
the weighted U with the un-weighted U. The two U statistics, however, are based on weights of different 
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scales (i.e., , 'i iw  vs. constant 1), therefore, a constant c is introduced to balance the two weight functions. The 
test statistic is then defined as, 
 
seq w uwWU U cU  , (3) 
where the scaling constant c can be obtained by minimizing the L2 norm distance between the two weight 
metrics, i.e.,
2
, '
0 '
arg min{ ( ) }i i
c i i
c w c
 
  . Alternatively, we could choose other types of c. For instance, we 
could obtain c by minimizing the L1 norm distance between the two weight metrics, i.e.,
, '
0 '
arg min{ | |}i i
c i i
c w c
 
  . 
Asymptotic distribution of the test statistic 
When the weighted U is significantly larger than the rescaled un-weighted U, we reject the null hypothesis 
and conclude there is an association between P genetic variants and the phenotype. The p-value can be 
obtained by comparing the observed test statistic, 
obs
seqWU , with the null distribution, i.e., Pr( )
obs
seq seqWU WU . 
For a small sample size, a permutation test can be used for the calculation of the p-value. However, for a large 
sample size and high-dimensional data, a permutation test could be computationally intense. Therefore, we 
derive the asymptotic distribution of seqWU to efficiently assess the significance level of the association. 
We first rewrite the test statistic, seqWU , of equation (3) as a weighted summation of , 'i is ,  
, ' , '
'
1
( 1)
seq i i i i
i i
WU k s
n n 


 ,        (4) 
where we define a new weight , ' , 'i i i ik w c  . Denote 1 2( , ,... )
T
NQ q q q  and , '{ }i i n nK k  . If the 
phenotypic similarity is measured by the cross product kernel, , ' 'i i i is q q , seqWU  is simplified to a quadratic 
form , ' '
'
( 1) Tseq i i i i
i i
n n WU q k q Q KQ

   , with all the diagonal elements of K  equal to 0 ( , 0i ik  ). In 
such a case, it has a close connection with the variance component score test in the linear mixed model, except 
that seqWU  does not use information from the diagonal terms ( , 0i ik  ), and does not assume a Gaussian 
distribution of the phenotype. 
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The limiting distribution of U depends on 1 1 2 2( ( ( , ) | ))Var E h Y Y Y  [Serfling 1981]. If 1 0  , the U 
statistic is a non-degenerated U and asymptotically follows a normal distribution. If 1 0  , the U statistic is 
a degenerated U and can be approximated by a mixture chi-squared distribution. By the definition of seqWU ,  
we have 1 2 2 2 1( | ) ( ) 0E q q q q E q  , and therefore 1 0  . Because 1 0  , seqWU  is a degenerated 
weighted U statistic. Its limiting distribution can be approximated as a linear combination of chi-squared 
random variables,  
2
1,
1 1
( 1)
n
seq m l ml
m l
nWU   

 
  ,       (5) 
where 
2
1,ml  are iid chi-squared random variables with 1 degree of freedom. l  and m are generated from 
the eigen-decomposition of the weight function , 'i ik  and the kernel function , 'i is [Serfling 1981; Shieh, et al. 
1994; Wet and Venter 1973]. l  (l=1,…,n) are obtained from the eigen-values l  of matrix , '{ }i i n nK k  , 
with / ( 1)l l n   . { }m  are the eigen-values of a general kernel function ( , )h , obtained from the 
following decomposition, 
1 2 1 2
1
( , ) ( ) ( )m m m
m
h q q q q  


 , 
where { ( )}m  are the ortho-normal eigenfunctions corresponding to m . For the cross product kernel, we 
can show that 1 2 1 2 1 1 1 2 1 2
2
( , ) 1 ( ) ( ) 0 ( ) ( )m m
m
h q q q q q q q q   


    , where 1( )q q   (Appendix S1). 
Thus, { 1}1m m  , where 1 is an indicator function, and 
1 1 1
( ) / ( 1) 0
n n
m l l
m l l
trace K n  

  
      . The 
limiting distribution of seqWU  can be simplified to 
2
,
D
seqnWU   , where 
2 2
, 1,
1
l l
l
  

 

  is a mixture 
chi-squared distribution with mean 0 and finite variance (Appendix A). Given the asymptotical distribution of 
seqWU , the p-value can then be calculated using the Davis method [Davies 1980]. 
Adjusting covariates with confounding effects 
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Assume we have J covariates, 1(1, , , )i i iJX x x , 1,2,...,i N . To adjust for the potential confounding 
effects, we will first fit the transformed value of the phenotype, 
1 2( , ,... )
T
NQ q q q , with covariates 
1 2( , ,..., )
T
NX X X X , and then use the residuals for the association test. Based on this idea, we project Q  
onto the space spanned by X , and obtain the prediction Qˆ , where 1ˆ ( )T TQ X X X X Q . Denoting 
1( )T TH I X X X X   and 2 ˆ ˆˆ ( ) ( ) / ( 1)TQ Q Q Q N J      , we can obtain the residuals, 
ˆ/eQ HQ  . It’s easily to show that eQ X , therefore, a new response vector is attained that is 
perpendicular to the space spanned by the covariates. The test statistic seqWU  can be reconstructed as 
, ' '
'
1
( 1)
e e
seq i i i i
i i
WU k q q
n n 


 . 
Using the same argument as above, seqWU  with covariates adjustment can also be approximated by a linear 
combination of chi-squared random variables, 
2
1,
1
~
n
e
seq l l
l
nWU  

 . 
/ ( 1)e el l n    and { }
e
l  are the eigen-values of matrix 
eK , where 
eK HKH . If the model is 
correctly specified and the covariates (e.g., principle components) can capture the confounding effects, the 
residual confounding is negligible. However, in practical, we should consider potential issues, such as 
nonlinearity of covariates and high correlations between genetic variables and covariates, before 
implementing the covariate adjusting approach. Directly using the approach without considering these issues 
may lead to inflated type I error or power loss. For instance, principle components from genetic data can be 
used to adjust for confounding effects due to population stratification or population admixture. Nevertheless, 
if the genetic variants and/or the number of principle components are insufficient, residual confounding could 
lead to inflated type I error[Price, et al. 2006]. 
Results  
Simulation 
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We conducted simulation studies to evaluate the performance of WU-SEQ, comparing it with one of the most 
commonly used methods, SKAT [Wu, et al. 2011]. For all of the simulations, we used genetic data from the 
1000 genome project [Abecasis, et al. 2010] to mimic the real sequencing data structure (e.g., LD pattern and 
allele frequency). Specifically, we used a 1Mb region from the genome (Chromosome 17: 7344328-8344327), 
and randomly chose a 30kb segment from that 1Mb region for each simulation replicate (if not specified 
otherwise). The average number of SNVs in the sampled 30kb segments is 194. The minor allele frequency 
(MAF) of the SNV in the genome region ranged from 4.50×10-4 to 4.99×10-1, with a distribution highly 
skewed to rare variants (34.8% of the variants with MAF<0.001, 69.1% of the variants with MAF<0.01 and 
80% of the variants with MAF<0.03). Similar to the SKAT simulation studies [Wu, et al. 2011], we selected a 
portion of the genetic variants with MAF<0.03 as functional SNVs. A number of individuals, ranging from 50 
to 500, were randomly chosen as the study samples from all of the available individuals in the 1000 genome 
project.  
For each disease model, we simulated 1000 data replicates and obtained the type 1 error and power for both 
WU-SEQ and SKAT. For SKAT, we used the link function according to the distributions of phenotype (i.e., 
the logit link for a binary phenotype and the identity link for a continuous phenotype) [Wu, et al. 2011]; for 
WU-SEQ, we used the L2 norm to choose the constant c and did not specify an assumption on the phenotype 
distribution. To be consistent, both methods used a weighted IBS to summarize genetic information. The type 
1 error and power were obtained by calculating the percentage of p-values smaller than 0.05 from 1000 data 
replicates. 
Simulation I 
We first simulated a series of disease models, without considering covariates, and investigated the influence of 
the direction and magnitude of effects on both methods. Each data replicate was comprised of 500 subjects. 
We considered 4 types of distributions for the phenotypes: binary, Gaussian, Student’s t with 2 degrees of 
freedom, and Cauchy. Binary and Gaussian phenotypes are typically observed in population-based studies. 
The Cauchy-distributed and t-distributed phenotypes represent continuous phenotypes with more extreme 
values (i.e., heavy tailed). We used the logistic model to simulate the binary phenotype, 
logit( ( 1))i iP y G    , 
where 
iG  and iy  were the genotype and phenotype of the i-th individual, respectively.   was a vector of 
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regression parameters, measuring the effects of the genetic variants. For each simulation replicate, we sampled 
an effect vector from a multivariate normal distribution,
2( 1, )MVN I   , where 1  was the vector of 1 and I 
was the identity matrix. For Gaussian phenotypes, we simulated the model as, 
i i iy G     , 
where 2~ (0, )i N  . For the t-distributed phenotype, we simulated the model as: 
2, ~i i i i dfy G t       . 
For the Cauchy type of phenotype, we used 
~ ( , )i iy cauchy a b . 
ai and b were the location parameter and the scale parameter of the Cauchy distribution, respectively, where
i ia G    and b was a fixed value. For all four types of phenotypes, we considered different directions of 
genetic effects. For the first scenario, we assumed 0  , whereby half of the functional SNVs were 
deleterious and half of the functional SNVs were protective. For the second scenario, we assumed 0  , 
whereby the majority of the functional SNVs were deleterious. For each scenario, we varied the percentage of 
functional SNVs from 5% to 50%. The details of the simulation setting are provided in Table S1. 
We summarized the results in Table 1. From Table 1, we can see that WU-SEQ had a well-controlled type 1 
error rate under various phenotype distributions. In contrast, SKAT had an inflated type 1 error rate when the 
underlying distribution was the Cauchy distribution (0.194) or t distribution (0.110). Similar to SKAT, 
WU-SEQ allows for different directions of genetic effects (i.e., both deleterious and protective effects). For 
both scenarios (i.e., 0  and 0  ), WU-SEQ obtained a power that was comparative to or a slightly 
higher power than SKAT. As the percentage of the functional SNVs increased, both WU-SEQ and SKAT 
gained improved power for binary and Gaussian phenotypes. For the Cauchy phenotype and t-distributed 
phenotype, however, the power of WU-SEQ was significantly higher than that of SKAT. With the Cauchy 
phenotype, for example, SKAT’s power ranged from 0.167 to 0.192 for 0   and ranged from 0.175 to 
0.199 for 0  , while the power of WU-SEQ increased from 0.116 to 0.635 for 0   and increased 
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from 0.095 to 0.818 for 0  . 
Simulation II 
In simulation II, we investigated the influence of sample size on the performance of WU-SEQ and SKAT. We 
used the same models as in simulation I to simulate binary, Gaussian, Student’s t and Cauchy phenotypes. For 
simplicity, we assumed 0  and a fixed 
2
 , and varied the sample size from 50 to 500 (Table S2). We 
assumed 0% of the genetic variants were functional for the null model, and assumed 50% of the genetic 
variants were functional for the disease models. 
The results were summarized in Table 2. Type 1 error rates of WU-SEQ were well controlled at the 0.05 level 
for different sample sizes (i.e., 50, 100, 200 and 500) and various phenotype distributions (i.e., binary, 
Gaussian, Student’s t and Cauchy), while the type 1 error of SKAT was inflated for the Cauchy phenotype 
(0.118~0.194) and the t-distributed phenotype (0.110~0.131). We also observed that both WU-SEQ and SKAT 
had conservative type I error rates when the study sample sizes were small. For instance, the type I error rates 
of SKAT and WU-SEQ were 0.001 and 0.005, respectively, when the sample size was 50 and the phenotype 
was binary. The power of WU-SEQ increased as the sample size increased for all four types of phenotypes. 
The power of SKAT remained almost the same for the Cauchy phenotype (0.126~0.177) when the sample size 
increased. For both the binary and Gaussian phenotypes, the power of WU-SEQ was comparable or slightly 
higher than that of SKAT, while the power of WU-SEQ was significantly higher than that of SKAT for the 
t-distributed and Cauchy-distributed phenotypes. 
Additional simulations were also conducted to evaluate the performance of WU-SEQ in the high-dimensional 
data setting. Instead of using a 30kb segment, we randomly chose a 500kb segment for each simulation 
replicate. The average number of SNV for each subject was increased from 194 to 1873. We fixed the sample 
sizes as 100 and simulated the phenotype by using the settings presented in Table S2. The result showed that 
WU-SEQ had well controlled type 1 error and good power performance when the number of SNVs was larger 
than the sample size (Table 3). 
Simulation III 
In genetic association analyses, we often need to adjust important covariates (e.g., gender) for potential 
confounding effects. Therefore, we conducted another set of simulations to investigate the performance of 
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WU-SEQ with the consideration of covariates adjustment. In this simulation, we simulated two covariates, 
1, ~ (0.3)ix Bernoulli  and 2, ~ (0,1)ix N  for each subject. The binary phenotype was simulated by using 
logit( ( 1))i i iP y X G      , 
where
1, 2,( , )i i iX x x  and 1 2( , )
T    were the covariates and the effects of the covariates, respectively. 
Similarly, we used the linear model for the Gaussian phenotype, 
2, ~ (0, )i i i i iy X G N         , 
and the following model for the t-distributed phenotype, 
2, ~i i i i i dfy X G t         . 
The Cauchy phenotype was simulated by using, 
~ ( , ),i iy cauchy a b where i i ia X G     . 
We varied the sample size from 50 to 500, and fixed the percentage of functional rare variants at 50% for the 
disease models (Table S3). 
The results were summarized in Table 4. We found that the projection method worked very well for WU-SEQ 
in terms of covariate adjustment, and the type I error was well-controlled under different phenotype 
distributions. SKAT, however, had a well-controlled type 1 error only when the underlying assumptions were 
satisfied and the link function was correctly specified. Similar to simulations I and II, we observed 
comparable power between WU-SEQ and SKAT for both the binary and Gaussian phenotypes, and WU-SEQ 
had significantly higher power than SKAT for the Cauchy and t-distributed phenotypes. We also found the 
type 1 error rates were less conservative for studies with the binary phenotype with covariate adjustment. This 
could be due to the fact that the increased levels of residuals after covariate adjustment lead to a better 
approximation of normal distribution. 
In addition to the above simulations, we conducted simulations to investigate the performance of WU-SEQ 
under different choices of c (Table 5) and different choices of U kernel (Table 6). For different c based on L1 
norm and L2 norm, WU-SEQ had well-controlled type I error. However, WU-SEQ based on L2 norm had 
slightly higher power than that based on L1 norm (Table 5). We also compared the U kernel with the qunatile 
 14 
 
transformation and that without the quantile transformation (by using ranks of phenotypes). Both approaches 
could control the type I error. Nevertheless, using the quantile transformation let to higher power for normal 
and t distributed phenotypes (Table 6). In simulation studies, we used 1000 simulated data replicates to access 
the type I errors of WU-SEQ at 0.05 level. We also conducted additional simulation studies by using 100000 
simulated data replicates to access the type I error of WU-SEQ at 5×10-4 level. The results (Table S4) showed 
that the type I error at 5×10-4 level is well controlled around 5×10-4. Moreover, the type I errors at 0.05 level 
were much closer to 0.05 by using 100000 simulated data replicates. 
Application to the sequencing data from the Dallas Heart Study 
To further evaluate the performance of WU-SEQ and SKAT, we applied both methods to the sequencing data 
from the Dallas Heart Study (DHS) [Romeo, et al. 2009]. The DHS sequencing data is comprised of 4 genes, 
ANGPTL3, ANGPTL4, ANGPTL5 and ANGPTL6. We were interested in evaluating the association of these 
genes with body mass index (BMI), cholesterol, and very low density lipoprotein cholesterol (VLDL). 
Following the previous study [Wu, et al. 2011], we considered age, gender, and race as covariates in the model. 
Prior to the association analysis, we re-assessed the quality of the genotype data. As a part of the quality 
assessment, we eliminated the SNVs and subjects that had a high missing rate. After the quality control, 230 
rare variants (54 SNVs, 63 SNVs, 61 SNVs, and 52 SNVs are from ANGPTL3, ANGPTL4, ANGPTL5 and 
ANGPTL6, respectively) and 2598 subjects remained for the analysis. In the analysis, random imputation 
based on allele frequency was used to impute missing genotypes. 
The distribution of the SNVs in the DHS was heavily skewed to the rare variants (Figure S2), wherein 93.5%, 
87.4%, and 70% of all SNVs had an MAF of less than 3%, 1% and 0.1%, respectively. Similar to previous 
studies [Wu, et al. 2011], we selected SNVs with an MAF<3% for the analysis in order to detect associations 
due to rare variants. The distributions of MAF for the 4 genes were given in Figure 1. From Figure 1, we can 
see that the distributions of MAF were highly skewed to the left, with the majority of the SNVs having an 
MAF<0.1%. The distributions of the three phenotypes, BMI, cholesterol and VLDL, can be viewed in Figure 
2. Among the three phenotypes, the distribution of VLDL was heavily skewed to the left, which is unlikely to 
follow the Gaussian distribution. We applied both WU-SEQ and SKAT to the association analyses of 4 genes, 
with the consideration of three covariates: gender, race and age (Table 7). To be consistent, we used weighted 
IBS for both WU-SEQ and SKAT. WU-SEQ detected a strong association of ANGPTL4 (p-value=0.007) with 
VLDL, while SKAT found only a marginal association (p-value=0.105). To further explore this finding, we 
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combined all 4 genes into a gene set, and then tested its association with VLDL (Table 7). The association 
remained significant (p-value=0.032) using WU-SEQ, but not SKAT (p-value=0.316). None of the 4 genes 
was found to be associated with BMI using either WU-SEQ or SKAT. A marginal association was detected 
between ANGPTL6 and cholesterol, with a p-value of 0.059 from WU-SEQ and a p-value of 0.025 from 
SKAT. To evaluate the performance of both methods for the binary phenotype, we dichotomized the data into 
a highest quartile (coded as 1), and a lowest quartile (coded as 0) for each phenotype (Table S5). Overall, 
WU-SEQ attained similar results to SKAT. For example, both methods found no association of all 4 genes 
with BMI, a marginal association of all 4 genes with cholesterol, and a significant association of all 4 genes 
with VLDL. 
Discussion 
Targeted, exome and whole-genome sequencing studies are now underway for the discovery of new genetic 
variants, particularly rare variants, associated with complex diseases. With the emerging of a large amount of 
high-dimensional sequencing data, great challenges have been posed to statistical analyses of sequencing data. 
Conventional single-locus analyses have been shown to have low power for analyzing sequencing data, not 
only because of the low frequencies of rare variants, but also because of the use of a more stringent 
significance threshold. Joint association analyses of multiple genetic markers, as demonstrated in several 
studies, can greatly reduce the dimensionality and obtain powerful performance for sequencing data [Li and 
Leal 2008; Madsen and Browning 2009; Neale, et al. 2011; Tzeng, et al. 2009; Wu, et al. 2011].  
Non-parametric methods, such as U-statistic-based methods, have shown great promise for high-dimensional 
data analysis, especially when the underlying phenotype distributions and modes of inheritance are unknown. 
Several U-statistic-based methods were recently adopted in genetic association studies to detect common 
variants underlying complex human diseases [Li 2012; Li, et al. 2011; Schaid, et al. 2005; Wei, et al. 2012; 
Wei, et al. 2013]. In this paper, we propose a non-parametric method, WU-SEQ, for testing the joint 
association of multiple SNVs with disease phenotypes. Built under the framework of the weighted U statistic, 
WU-SEQ is robust against different underlying distributions of phenotypes. As demonstrated by the 
simulation study, WU-SEQ had well-controlled type 1 errors and attained high power under binary, Gaussian, 
t-distributed and Cauchy phenotypes. In contrast, the performance of existing methods, such as SKAT, 
depends on satisfaction of the underlying assumptions. If the assumptions were violated (e.g., the distribution 
followed a heavy-tailed distribution such as Cauchy), SKAT had an inflated type 1 error, and had low power 
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to detect an association. Although SKAT can handle classic types of phenotypes (e.g., the exponential family) 
by using appropriate link functions, WU-SEQ can be applied to a wider range of phenotypes without any 
distribution assumptions. In this paper, we used the normal quantile to build the test statistic. Alternatively, 
one can also use rank to construct the test statistic. When the sample size is sufficiently large, we expect that 
using quantile and using rank would have similar results. Nevertheless, for small sample sizes, using a normal 
quantile could be more powerful and less conservative than using rank. Yet, when the distribution is heavily 
tailed (e.g., Cauchy), using rank could attain a slight advantage than using quantile (e.g., having a 
well-controlled type I error) for small sample sizes (Table 6). As a similarity-based method, WU-SEQ is 
flexible, to accommodate various types of data. The genetic variants used to construct genetic similarity are 
not constrained to categorical data (e.g. SNV); they can also be count data (e.g., CNV) and continuous data 
(e.g., expression data). For high-dimensional sequencing data, the number of genetic variants evaluated in the 
association analyses can be large. We have showed in the simulation studies, when the number of variants was 
much larger than sample sizes, WU-SEQ could still control type I error and have good power performance 
(Table 3). Similar as existing methods (e.g., SKAT), WU-SEQ is gene/region based methods, and therefore can 
be directly applied to whole-exome sequencing data. Nevertheless, challenges remain when applying the 
method to whole-genome sequencing data because it requires a prior determination of a region or a functional 
unit (e.g., gene). In addition, potential issues, such as determining genome-wide significance, also need to be 
carefully considered for whole-genome sequencing data analysis. Although research has been initiated to 
address these issues[Xu, et al. 2014], further investigation is much needed on these topics. 
In WU-SEQ, we first summarize the information from multiple markers into genetic similarities, and then 
evaluate the genetic similarities with the corresponding phenotypic similarities. If the genetic similarities are 
concordant with the trait similarities, we anticipate a large value of the test statistic, from which we could 
infer an association. In this paper, we use a weighted IBS to construct genetic similarity, which assigns more 
weights to rare variants. Other types of genetic similarity metrics can also be used, such as those consider 
interactions. Prior knowledge can also be incorporated, by assigning different weight for each variant 
according to their biological plausibility. To measure the phenotype similarity, we use the cross product kernel,
, ' ' '( , )i i i i i is h q q q q  , which lead to nice asymptotic properties of the test statistic. Nevertheless, we can use 
other types of kernel functions for the phenotype similarity. If the kernel function satisfies two regularity 
conditions, 
2
1 2( ( , ))FE h Y Y   and 1 2 2( ( ( , ) | )) 0Var E h Y Y Y  , we can calculate the asymptotic p-value by 
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approximating the weighted U to a linear combination of chi-squared variables. Even if the two conditions are 
not satisfied, we can still use permutation to obtain the p-value of the association test. The choice of the 
genetic- or phenotype-similarity metrics depends on the underlying disease model, which could lead to 
different performance. For example, when the percentage of risk variants increases and/or when the effect 
sizes of risk variants follow one direction, the burden tests are expected to be more powerful than WU-SEQ. 
In this case, we can use genetic similarities accommodating the underlying disease models. One of the 
strategies is to first collapse all genetic variants by weighted sum and then calculate the genetic similarity. 
Although joint association analyses greatly reduce the dimensionality for sequencing data, the computation 
could be intense if a permutation test is used. We derived the asymptotic distribution for WU-SEQ to facilitate 
the high-dimensional data analysis. When the sample size of a study is small, asymptotic properties may not 
hold and a permutation test can be used. We also use a projection method in WU-SEQ to take covariates into 
account. Through simulations and a real data analysis, we found the covariate-adjusted WU-SEQ was robust 
to different types of phenotype distributions. In addition, we found that WU-SEQ had almost the same power 
as SKAT when the phenotype followed Gaussian distribution and covariates were not considered. The reason 
is that SKAT uses a variance component score test, and WU-SEQ has a close connection with the variance 
component score test for the Gaussian-distributed phenotype. In fact, when covariates are not considered, 
SKAT can be viewed as a special case of WU-SEQ by using the cross product kernel without quantile 
transformation. When covariates are considered, especially when the phenotype does not follow the Gaussian 
distribution (i.e. the link function in SKAT is not an identity link), WU-SEQ could attain more computational 
efficiency than SKAT. In SKAT, one needs to first fit the null model using a generalized linear model, which 
involves iterative estimation. Furthermore, the calculation of a projection matrix in SKAT involves additional 
matrix multiplications (i.e., calculating 
1( )T TH V VX X VX X V   in SKAT vs. calculating
1( )T TH I X X X X   in WU-SEQ, where V  is the covariance matrix estimated from the null model), 
and the calculation of the limiting distribution in SKAT involves an additional large matrix decomposition (i.e., 
calculating 
1/2 1/2H KH , where 
1/2H  need to be calculated from an eigen-decomposition of the H  matrix). 
The covariate-adjusted WU-SEQ does not require iterative estimation and needs less matrix multiplication and 
decomposition, which offers a greater computational advantage over SKAT. 
In the analysis of the DHS study, WU-SEQ detected a strong association of ANGPTL 4 with VLDL. By 
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further studying the distribution of VLDL, we found the distribution was heavily skewed, which does not fit 
the normal assumption. The advantages of WU-SEQ are not limited to this specific case; the method could be 
useful for other cases (e.g., small sample sequencing studies and sequencing studies with extreme-phenotype 
design). A recent version of SKAT also considers the extreme phenotype by assuming a truncated Gaussian 
distribution[Barnett, et al. 2013]. While SKAT needs to make adjustments and certain assumptions for the 
truncated distribution of extreme phenotypes WU-SEQ, as a non-parametric method, can be directly applied 
to studies with extreme-value phenotypes. 
Appendices 
Appendix A 
We first introduce a regularity condition on the weight function 
, 'i ik . Because , '0 1i iw   and 
, ' , 'i i i ik w c  , we have , '0 | | 'i ik c  , where 'c  is a positive constant. Based on this, we have 
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Based on this result, we can conclude that 
2 2
, 1,
1
l l
l
  

 

  has zero mean and finite variance. Additionally, the 
results implies that seqnWU   is degenerated, i.e., 0
p
seqnWU  . 
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Tables: 
 
Table 1: Type I error and power comparisons of WU-SEQ and SKAT under different direction and magnitude 
of effects 
Effect* Pct** Binary Normal Student’s t Cauchy 
 
 SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ 
Type I Error 
Null 0 0.037 0.037 0.037 0.043 0.110 0.038 0.194 0.041 
Power 
A1 
5 0.281 0.284 0.174 0.185 0.164 0.193 0.167 0.116 
10 0.417 0.423 0.315 0.329 0.212 0.331 0.160 0.201 
30 0.828 0.841 0.675 0.688 0.369 0.695 0.192 0.451 
50 0.935 0.944 0.856 0.869 0.525 0.880 0.177 0.635 
A2 
5 0.065 0.073 0.085 0.093 0.140 0.134 0.190 0.095 
10 0.166 0.173 0.155 0.163 0.192 0.288 0.175 0.179 
30 0.539 0.547 0.524 0.527 0.471 0.784 0.199 0.578 
50 0.773 0.780 0.790 0.798 0.733 0.960 0.187 0.818 
* “Null” corresponds to the null model with no functional variant; “A1” corresponds to the setting where half of the 
functional rare variants have deleterious effect and the other half of functional rare variants have protective effect; “A2” 
corresponds to the setting where all the functional rare variants have deleterious effects. 
** Percentage of functional rare variants. 
 
Table 2: Type I error and power comparisons of WU-SEQ and SKAT for different sample sizes 
Effect* Sample size Binary Normal Student’s t Cauchy 
 
 SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ 
Type I Error 
Null 
50 0.001 0.005 0.027 0.047 0.117 0.044 0.118 0.041 
100 0.007 0.013 0.035 0.050 0.131 0.051 0.134 0.052 
200 0.022 0.029 0.029 0.039 0.121 0.043 0.165 0.056 
500 0.037 0.037 0.037 0.043 0.110 0.038 0.194 0.041 
Power 
A1 
50 0.016 0.035 0.145 0.177 0.160 0.164 0.126 0.086 
100 0.119 0.181 0.279 0.318 0.220 0.296 0.160 0.164 
200 0.494 0.536 0.521 0.545 0.317 0.557 0.178 0.291 
500 0.935 0.944 0.856 0.869 0.525 0.880 0.177 0.635 
* “Null” corresponds to the null model with no functional variant, “A1” corresponds to the setting where half of the 
functional rare variants have deleterious effect and the other half of functional rare variants have protective effect. 
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Table 3: Type I error and power comparisons of WU-SEQ and SKAT when number of variants is much larger 
than sample size* 
Effect Method Distribution 
  Binary Normal Student’s t Cauchy 
  Type I Error    
Null SKAT 0.007 0.021 0.130 0.196 
 WU-SEQ 0.012 0.059 0.042 0.059 
  Power    
A1 SKAT 0.153 0.896 0.708 0.264 
 WU-SEQ 0.304 0.933 0.864 0.558 
*The average number of SNVs is 1873 in these settings, while the sample size is set as 100. The effect sizes is set as the 
same as in Table S2 
 
Table 4: Type I error and power comparisons of WU-SEQ and SKAT for covariate adjustment 
Effect Sample size Binary Normal Student’s t Cauchy 
 
 SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ 
Type I Error 
Null 
50 0.027 0.027 0.040 0.059 0.084 0.069 0.128 0.063 
100 0.030 0.034 0.042 0.054 0.106 0.064 0.131 0.065 
200 0.028 0.028 0.036 0.050 0.110 0.060 0.173 0.061 
500 0.036 0.036 0.043 0.048 0.115 0.065 0.194 0.047 
Power 
A1 
50 0.060 0.071 0.128 0.165 0.297 0.400 0.140 0.112 
100 0.156 0.210 0.306 0.342 0.483 0.664 0.164 0.159 
200 0.522 0.545 0.500 0.527 0.682 0.882 0.163 0.262 
500 0.929 0.934 0.850 0.855 0.884 0.997 0.180 0.554 
* “Null” corresponds to the null model with no functional variant; “A1” corresponds to the setting where half of the 
functional rare variants have deleterious effect and the other half of functional rare variants have protective effect. 
 
 
Table 5: Type I error and power comparisons of WU-SEQ by using different c* 
Effect Method Distribution 
  Binary Normal Student’s t Cauchy 
Type I Error 
Null WU-SEQL1** 0.013 0.048 0.056 0.041 
 WU-SEQL2*** 0.013 0.049 0.058 0.043 
Power 
A1 WU-SEQL1 0.164 0.313 0.300 0.150 
 WU-SEQL2 0.170 0.322 0.306 0.159 
*The sample size for this simulation is 100 and the effect sizes is set as the same as in Table S2. 
**In WU-SEQL1, we choose c by using L1 norm. 
***In WU-SEQL2, we choose c by using L2 norm. 
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Table 6: Type I error and power comparison of WU-SEQ by using normal quantile or rank* 
Effect Method Distribution 
  Binary Normal Student’s t Cauchy 
Type I Error 
Null WU-SEQRK** 0.017 0.02 0.031 0.032 
 WU-SEQQT*** 0.017 0.047 0.057 0.050 
Power 
A1 WU-SEQRK 0.161 0.243 0.304 0.181 
 WU-SEQQT 0.161 0.314 0.322 0.169 
*The sample size for this simulation is 100 and the effect sizes is set as the same as in Table S2. 
**In WU-SEQRK, we use cross product kernel based on rank of the phenotype value without quantile transformation. 
***In WU-SEQQT, we use cross product kernel with quantile transformation. 
 
 
Table 7: The association of 4 candidate genes with 3 continuous phenotypes (i.e., BMI, Cholesterol, and 
VLDL) in the Dallas Heart Study  
 
Gene BMI Cholesterol VLDL 
 
SKAT WU-SEQ SKAT WU-SEQ SKAT WU-SEQ 
ANGPTL3 0.633 0.752 0.559 0.662 0.471 0.198 
ANGPTL 4 0.121 0.255 0.16 0.316 0.105 0.007 
ANGPTL 5 0.633 0.607 0.95 0.926 0.683 0.664 
ANGPTL 6 0.874 0.773 0.025 0.059 0.433 0.453 
All 4 genes 0.503 0.641 0.117 0.373 0.316 0.032 
* P-value from the association analysis, adjusting for age, gender, and race. 
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Figure 1: Distribution of SNVs with MAF<0.03 for the 4 genes in the Dallas Heart Study 
 
 
 
 
Figure 2: Distributions of the 3 phenotypes in the Dallas Heart Study 
 
 
 
 
 
